Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Blagg

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|June 26, 2015
Aurora kinase inhibition: a new light in the sky?Spiros Linardopoulos, Julian Blagg
Cancer Cell|July 12, 2017
Choose and Use Your Chemical Probe Wisely to Explore Cancer BiologyJulian Blagg, Paul Workman
Current Opinion in Pharmacology|September 2, 2014
Chemical biology approaches to target validation in cancerJulian Blagg, Paul Workman
Cell Chemical Biology|August 28, 2018
Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in CancerTeresa Kaserer, Julian Blagg
Cancer Cell|August 16, 2017
Choose and Use Your Chemical Probe Wisely to Explore Cancer BiologyJulian Blagg, Paul Workman
Nature Chemical Biology|August 30, 2011
Epigenetics: Targeting leukemia on the DOTJon Travers, Julian Blagg, Paul Workman
Journal of Chemical Information and Modeling|September 27, 2012
Plane of best fit: a novel method to characterize the three-dimensionality of moleculesNicholas C Firth, Nathan Brown, Julian Blagg
Journal of Chemical Information and Modeling|September 1, 2011
Scaffold diversity of exemplified medicinal chemistry spaceSarah R Langdon, Nathan Brown, Julian Blagg
Bioorganic & Medicinal Chemistry Letters|February 2, 2008
1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinityGavin A Whitlock, Julian Blagg, Paul V Fish
Drug Discovery Today|September 11, 2007
Designing drugs for the treatment of female sexual dysfunctionAlan D Brown, Julian Blagg, David S Reynolds
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|June 26, 2015
Aurora kinase inhibition: a new light in the sky?Spiros Linardopoulos, Julian Blagg
Cancer Cell|July 12, 2017
Choose and Use Your Chemical Probe Wisely to Explore Cancer BiologyJulian Blagg, Paul Workman
Current Opinion in Pharmacology|September 2, 2014
Chemical biology approaches to target validation in cancerJulian Blagg, Paul Workman
Cell Chemical Biology|August 28, 2018
Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in CancerTeresa Kaserer, Julian Blagg
Cancer Cell|August 16, 2017
Choose and Use Your Chemical Probe Wisely to Explore Cancer BiologyJulian Blagg, Paul Workman
Nature Chemical Biology|August 30, 2011
Epigenetics: Targeting leukemia on the DOTJon Travers, Julian Blagg, Paul Workman
Journal of Chemical Information and Modeling|September 27, 2012
Plane of best fit: a novel method to characterize the three-dimensionality of moleculesNicholas C Firth, Nathan Brown, Julian Blagg
Journal of Chemical Information and Modeling|September 1, 2011
Scaffold diversity of exemplified medicinal chemistry spaceSarah R Langdon, Nathan Brown, Julian Blagg
Bioorganic & Medicinal Chemistry Letters|February 2, 2008
1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinityGavin A Whitlock, Julian Blagg, Paul V Fish
Drug Discovery Today|September 11, 2007
Designing drugs for the treatment of female sexual dysfunctionAlan D Brown, Julian Blagg, David S Reynolds
Pageof 9